ecancermedicalscience

Review

Dihydropyrimidine dehydrogenase (DPD) polymorphisms knocking on the door

17 Jan 2022
Mauro Daniel Spina Donadio, Dirce Maria Carraro, Giovana Tardin Torrezan, Celso Abdon Lopes de Mello

Identifying polymorphisms in the dihydropyrimidine dehydrogenase (DPYD) genes is gaining importance as predictors of fluoropyrimidine-associated toxicity. The recommendation of dose adjustment for chemotherapy guided by the presence of polymorphisms of the DPYD gene can potentially improve treatment safety for a large number of patients, saving lives, avoiding complications and reducing health care costs. This article discusses how personalisation of fluoropyrimidine treatment based on the identification of DPYD variants can mitigate toxicities and be cost effective.

Related Articles

Agodirin Olayide, Chijioke Chijindu, Mustapha Fathi, Rahman Ganiyu, Olatoke Samuel, Olaogun Julius, Akande Halima
Ranti Ghosh, Debarshi Lahiri, Debjit Ghosh, Kushal Sen, Debanjan Chakraborty, Tapas Maji, Suparna Mazumder, Ranajit Mandal, Arit Bhattacharjee, Jayanta Chakrabarti
Shubham Dokania, Ajay K Choubey, Shashank Tiwari, Prasenjit Nath, Jhansi Pattanaik, Sambit S Nanda, Ashutosh Mukherji, Satyajit Pradhan
Chinomso Ugochukwu Nwozichi, Omolabake Salako, Anita Frimpomaa Oppong, Margaret Olutosin Ojewale
Anass Baladi, Hassan Abdelilah Tafenzi, Fatim-Zahra Megzar, Ibrahima Kalil Cisse, Othmane Zouiten, Leila Afani, Ismail Essaadi, Mohammed El Fadli, Rhizlane Belbaraka